Attached files

file filename
EX-99.1 - PRESS RELEASE, DATED NOVEMBER 8, 2011 - Option Care Health, Inc.pressrelease.htm

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 


______________________________________________



FORM 8-K
 

______________________________________________



 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) November 8, 2011
 


 
______________________________________________

 
BIOSCRIP, INC.
(Exact name of Registrant as specified in its charter)
 


______________________________________________


 
         
Delaware
 
0-28740
 
05-0489664
(State of Incorporation)
 
(Commission File Number)
 
(I.R.S. Employer
Identification No.)

 
     
100 Clearbrook Road, Elmsford, New York
 
10523
(Address of principal executive offices)
 
(Zip Code)
 

 
Registrant’s telephone number, including area code: (914) 460-1600
 
N/A
(Former name or former address, if changed since last report)
 


______________________________________________


 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 
 
 

Item 2.02 Results of Operations and Financial Condition.
 
 
On November 8, 2011, BioScrip, Inc. (the “Company”) issued a press release reporting its 2011 third quarter financial results. A copy of that press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
 
The press release includes certain non-GAAP financial measures as described therein. As required by Regulation G, reconciliation between any non-GAAP financial measures presented and the most directly comparable GAAP financial measures is also provided.
 
As provided in General Instruction B.2 to Form 8-K, the information furnished in this Item 2.02 and in Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange Commission, except as shall be expressly provided by specific reference in such filing.
 

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits

The following exhibits are being filed herewith:
         
Exhibit No.
 
Description
         
 
99.1
   
Press Release, dated November 8, 2011.
         
         
         
         
         
         


 
 
 
 



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
         
   
BIOSCRIP, INC.
     
     
     
Date: November 8, 2011
     
/s/ Richard M. Smith
   
By:
 
Richard M. Smith
       
President and Chief Executive Officer